A multicentre study using the chemotherapy combination of bi-monthly Xeloda and Eloxatin, with the addition of Avastin, in patients with advanced colorectal cancer

ABSTRACT: Study hypothesis: Bi-monthly dose intensified capecitabine (Xeloda) and oxaliplatin (Eloxatin) with concurrent bevacizumab (Avastin) will be a tolerable, effective, drug combination in the treatment of advanced colorectal cancer. Primary outcome(s): Progression free survival

DISEASE(S): Advanced Colorectal Cancer

PROVIDER: 2417225 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR